Safety and Efficacy Clinical Trial
Official title:
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
CART therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with high risk multiple myeloma after auto-HSCT.To test the safety and efficacy of giving targeting CD19 and BCMA T cells in treating high risk multiple myeloma followed with auto-HSCT.
Adults ages 18-75 with high risk Multiple Myelomas (R-ISS III stage or with extramedullary infiltration or with del(17p), t(4;14), t(14;16), t(14;20), 1q21+ or disease progression during treatment). Design: Participants may be screened with: Medical history Physical exam Blood and urine tests Heart tests Bone marrow sample Multiple scans and X-rays Participants will have apheresis. Blood is removed through a needle in an arm. T cells are removed. The rest of the blood is returned through a needle in the other arm. The cells will be changed in a laboratory. Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the T cells through the IV within 3 days. Maintenance therapy with IMiDs was received after combined CAR T infusion. After this, participants will stay in the hospital for at least 9 days and stay nearby for 2 weeks. Then they will have blood tests and see a doctor. Participants will visit the clinic 1, 2, 3, 6, 9 and 12 months after the infusion, then every 3 months until disease progression. A bone marrow sample will be taken at the 3-month visit. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04994210 -
Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL
|
Phase 2 | |
| Terminated |
NCT05247957 -
NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
N/A | |
| Completed |
NCT04621123 -
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
|
Phase 2 | |
| Recruiting |
NCT05140616 -
Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05349552 -
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
|
||
| Completed |
NCT03820596 -
Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05556889 -
Safety and Analgesic Efficacy of a Modified Auriculotemporal Nerve Block
|
N/A | |
| Recruiting |
NCT04446806 -
Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
|
Phase 4 | |
| Not yet recruiting |
NCT06244537 -
Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
|
N/A | |
| Completed |
NCT04785170 -
Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals
|
N/A | |
| Recruiting |
NCT04677452 -
Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM
|
Phase 1 | |
| Completed |
NCT01305044 -
The HEALS Project - Health Education and Active Living for Surviving Seniors
|
Phase 2 | |
| Active, not recruiting |
NCT04646590 -
A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19
|
Phase 3 | |
| Recruiting |
NCT05021276 -
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
|
Phase 4 | |
| Not yet recruiting |
NCT05008666 -
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
|
Phase 2 | |
| Recruiting |
NCT06066840 -
Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
|
Phase 4 | |
| Active, not recruiting |
NCT04852068 -
A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)
|
Phase 3 |